Lozano R, Balaguer A
Medical Department, Laboratorios Novag, S.A., Barcelona, Spain.
Clin Ther. 1991 Mar-Apr;13(2):281-8.
The subjects were 6,033 outpatients, from every province of Spain, with acute bronchitis (44%), exacerbation of chronic bronchitis (35%), typical pneumonia (14%), or atypical pneumonia (8%). Most of the patients were aged 50 to 70 years. The dose of josamycin in over 90% of the patients was 2 gm daily. The mean duration of infection before treatment was 5.3 days and treatment lasted a mean of 9.2 days. Concomitant drugs were taken by 78% of the patients; these included mucolytic agents, xanthine derivatives, beta-adrenergic agonists, and corticosteroids. After two weeks of treatment, the infection was cured in 82% of the patients with acute bronchitis, in 30% with chronic bronchitis, in 85% with typical pneumonia, and in 85% with atypical pneumonia; improvement was shown by 16%, 66%, 13%, and 13%, respectively. Treatment side effects were noted in 11% of the patients receiving josamycin alone and in 17% of the patients receiving concomitant drugs. Most side effects were mild and transient; treatment was discontinued because of side effects in 2% of the patients receiving josamycin alone and in 3% receiving concomitant drugs. It is concluded that josamycin is a safe and effective agent in the treatment of bronchopulmonary infections.
研究对象为来自西班牙各省的6033名门诊患者，其中患急性支气管炎的占44%，慢性支气管炎急性加重的占35%，典型肺炎的占14%，非典型肺炎的占8%。大多数患者年龄在50至70岁之间。90%以上患者的交沙霉素剂量为每日2克。治疗前感染的平均持续时间为5.3天，治疗平均持续9.2天。78%的患者服用了伴随药物；这些药物包括黏液溶解剂、黄嘌呤衍生物、β - 肾上腺素能激动剂和皮质类固醇。治疗两周后，急性支气管炎患者中82%的感染得到治愈，慢性支气管炎患者中这一比例为30%，典型肺炎患者中为85%，非典型肺炎患者中为85%；分别有16%、66%、13%和13%的患者病情有所改善。单独接受交沙霉素治疗的患者中有11%出现治疗副作用，接受伴随药物治疗的患者中有17%出现副作用。大多数副作用轻微且短暂；单独接受交沙霉素治疗的患者中有2%因副作用停药，接受伴随药物治疗的患者中有3%因副作用停药。结论是交沙霉素是治疗支气管肺部感染的一种安全有效的药物。
